Citi Pharma Limited (CPHL): Initiating Coverage with a ‘Buy’ Expansion & Diversification to drive earnings – By Topline Research

<p></p><p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">We initiate coverage on Citi Pharma Limited (CPHL), Pakistan&rsquo;s largest and only listed manufacturer of Active Pharmaceutical Ingredient (API), with a &lsquo;Buy&rsquo; rating and June-2023 Target Price of Rs47/share, offering a potential total return of 44% (including dividend yield of 6%).</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">CPHL is geared to reap the benefits of (i) favorable country demographics, (ii) increasing chronic/other diseases, (iii) rising health awareness, (iv) low per capita health care expenditure &amp; its potential to grow, and (v) GoP&rsquo;s increased focus on healthcare sector</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;...